NASDAQ:SPRY ARS Pharmaceuticals Q2 2025 Earnings Report $17.90 +0.21 (+1.19%) Closing price 04:00 PM EasternExtended Trading$17.90 0.00 (0.00%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast ARS Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.42Beat/MissN/AOne Year Ago EPSN/AARS Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$12.92 millionBeat/MissN/AYoY Revenue GrowthN/AARS Pharmaceuticals Announcement DetailsQuarterQ2 2025Date8/5/2025TimeBefore Market OpensConference Call DateWednesday, August 6, 2025Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile ARS Pharmaceuticals Earnings HeadlinesARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Consensus Price Target from BrokeragesJuly 14 at 2:57 AM | americanbankingnews.comARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle EpinephrineJuly 10, 2025 | seekingalpha.comThis Cold War “Accident” Could Unleash New $100 Trillion AI BoomObscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.July 14 at 2:00 AM | Brownstone Research (Ad)ARS Pharmaceuticals: 'Betting On The Come'July 9, 2025 | seekingalpha.comJim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”June 15, 2025 | msn.comARS Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 27, 2025 | globenewswire.comSee More ARS Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ARS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARS Pharmaceuticals and other key companies, straight to your email. Email Address About ARS PharmaceuticalsARS Pharmaceuticals (NASDAQ:SPRY) (NASDAQ: SPRY) is a clinical-stage biopharmaceutical company dedicated to developing non-opioid therapies for acute pain and allergic conditions. The company’s proprietary drug discovery platform integrates high-throughput peptide screening with a novel vascular targeting technology designed to deliver therapeutic candidates directly to sensory nerve endings. By modulating receptor-mediated pathways involved in pain and itch transmission, ARS aims to provide fast-acting relief with a reduced risk of systemic side effects. The company’s lead product candidate, CNV301, is in clinical development for emergency and procedural acute pain and is formulated for rapid onset and targeted action. ARS’s allergic disease program includes FRAGM-137, an intranasal peptide designed to alleviate seasonal and perennial allergic rhinitis, and FRAGM-189, which is being explored for skin and ocular manifestations of allergy. These candidates leverage the same platform technologies to address distinct therapeutic areas, underscoring ARS’s commitment to innovation across both pain management and allergy relief. Founded in 2003 and headquartered in Van Nuys, California, ARS Pharmaceuticals combines in-house development expertise with strategic collaborations to advance its pipeline. The company has entered partnerships and licensing agreements to facilitate global development and commercialization of select candidates. ARS is led by President and Chief Executive Officer David Bourne, who brings extensive biopharma experience in clinical development and corporate strategy. The company’s multidisciplinary team of scientists and clinicians works to translate novel receptor-targeting approaches into safe and effective treatments.Written by Jeffrey Neal JohnsonView ARS Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025)Bank of America (7/16/2025)The Goldman Sachs Group (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
